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Abstract
Nebivolol is a third generation beta blocker with endothelial nitric oxide synthase 
(eNOS) agonist properties. Considering the role of reactive oxygen species (ROS) 
in the uncoupling of eNOS, we hypothesized that the preadministration of an anti-
oxidant as tempol, could improve the hypotensive response of nebivolol in normo-
tensive animals increasing the nitric oxide (NO) bioavailability by a reduction of 
superoxide (O2.-) basal level production in the vascular tissue.
Male Sprague Dawley rats were given tap water to drink (control group) or tem-
pol (an antioxidant scavenger of superoxide) for 1 week. After 1 week, Nebivolol, at 
a dose of 3 mg/kg was injected intravenously to the control group or tempol treated 
group. Mean arterial pressure, heart rate and blood pressure variability were evalu-
ated in the control, tempol, nebivolol and tempol nebivolol groups, as well as, the 
effect of different inhibitor as NW-nitro-l-arginine methyl ester (L-NAME, a Nitric  
oxide synthase blocker) or glybenclamide, a KATP channel inhibitor. Also, the  
expression of α,β soluble guanylate cyclase (sGC), phospho-eNOS, and phospho-
vasodilator-stimulated phosphoprotein (P-VASP) were evaluated by Western  
Blot and cyclic guanosine monophosphate (cGMP) levels by an enzyme-linked 
immunosorbent assay (ELISA) commercial kit assay.
We showed that preteatment with tempol in normotensive rats produces a  
hypotensive response after nebivolol administration through an increase in the NO 
bioavailability and sGC, improving the NO/ cGMP/ protein kinase G (PKG) pathway 
compared to the nebivolol group.
We demonstrated that tempol preadministration beneficiates the response of a 
third generation beta blocker with eNOS stimulation properties, decreasing the basal 
uncoupling of eNOS and improving NO bioavailability. Our results clearly open a 
possible new strategy therapeutic for treating hypertension.
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Abstract 
Nebivolol is a third generation beta blocker with endothelial nitric oxide 
synthase (eNOS) agonist properties. Considering the role of reactive oxygen 
species (ROS) in the uncoupling of eNOS, we hypothesized that the 
preadministration of an antioxidant as tempol, could improve the hypotensive 
response of nebivolol in normotensive animals increasing the nitric oxide (NO) 
bioavailability by a reduction of superoxide (O2.-) basal level production in the 
vascular tissue. 
Male Sprague Dawley rats were given tap water to drink (control group) 
or tempol (an antioxidant scavenger of superoxide) for 1 week. After 1 week, 
Nebivolol, at a dose of 3 mg/kg was injected intravenously to the control group 
or tempol treated group. Mean arterial pressure, heart rate and blood pressure 
variability were evaluated in the control, tempol, nebivolol and tempol nebivolol 
groups, as well as, the effect of different inhibitor as NW-nitro-l-arginine methyl 
ester (L-NAME, a Nitric oxide synthase blocker) or glybenclamide, a KATP 
channel inhibitor. Also, the expression of α,β soluble guanylate cyclase (sGC), 
phospho-eNOS, and phospho-vasodilator-stimulated phosphoprotein (P-VASP) 
were evaluated by Western Blot and cyclic guanosine monophosphate (cGMP) 
levels by an enzyme-linked immunosorbent assay (ELISA) commercial kit 
assay. 
We showed that preteatment with tempol in normotensive rats produces 
a hypotensive response after nebivolol administration through an increase in the 
NO bioavailability and sGC, improving the NO/ cGMP/ protein kinase G (PKG) 
pathway compared to the nebivolol group. 
We demonstrated that tempol preadministration beneficiates the 
response of a third generation beta blocker with eNOS stimulation properties, 
decreasing the basal uncoupling of eNOS and improving NO bioavailability. Our 
results clearly open a possible new strategy therapeutic for treating 
hypertension. 
Keywords: antioxidants, cardiovascular therapeutic, endothelial nitric oxide, 
nitric oxide, oxidative stress, third generation beta blockers. 
Abbreviations 
cyclic guanosine monophosphate , cGMP; endothelial nitric oxide 
synthase; enzyme-linked immunosorbent assay , ELISA; eNOS; guanosine-5'-
triphosphate , GTP; heart rate, HR; hydrogen peroxide , H2O2 ; low frequency 
range , LF; mean arterial pressure, MAP; NW-nitro-l-arginine methyl ester, L-
NAME; nitric oxide, NO; NO metabolites content, NOx; peroxynitrite , ONOO-; 
phospho- vasodilator-stimulated phosphoprotein , P-VASP; protein kinase G, 
PKG; reactive oxygen species, ROS; soluble guanylate cyclase, sGC; 
superoxide, O2.-; thiobarbituric acid reactive substances, TBARS; very low 
frequency range, VLF. 
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1. Introduction 
Oxidative stress is an imbalance between the production and 
degradation of reactive oxygen species (ROS), such as O2.- and hydrogen 
peroxide (H2O2), thereby leading to cellular and tissue injury due to the high 
reactivity properties of these oxygen species [1]. The damage inflicted by ROS, 
as well as, reactive nitrogen species such as peroxynitrite (ONOO-) on cellular 
and extracellular targets as membrane lipids [2], proteins [3], and 
deoxyribonucleic acid [4] contributes to tissue and organ dysfunction in several 
pathologies such as hypertension among others [5]. O2.- and H2O2 produced 
mainly by the NADPH oxidases in vascular cells are two of the most biologically 
important ROS in the cardiovascular system [6-8]. Importantly, NAD(P)H 
production of O2.- is constitutive conversely to the phagocytic isoform that is only 
activated when the respiratory burst [5]. Constitutive production leads to basal 
level of O2.- also in normotensive animals [9]. In the vasculature, O2.- reacts with 
NO from the eNOS to form ONOO-, a potent oxidant compound, leading to 
uncouple the eNOS [10]. Uncoupling of eNOS generates O2.- instead of NO. As 
a consequence, the loss of bioavailable NO and formation of ONOO- lead to 
vascular inflammation and remodeling, altered vascular tone, enhanced 
vascular permeability, and increased platelet aggregation not only in 
hypertensive patients, but also in normotensive subjects, Consequently, eNOS 
uncoupling and reduced endothelium-dependent relaxation impair vascular 
function that leading to hypertension [7,10]. 
The third generation beta blocker nebivolol represents an attractive 
option for the treatment of different cardiovascular diseases, including 
hypertension and cardiac failure. Beneficial properties of nebivolol include the 
highly selective blockade of the β1-adrenoceptor and enhancement of NO 
dependent vasodilation [11-12]. 
Tempol is an antioxidant that mimics the action of the superoxide 
dismutase enzyme, that catalyses the conversion of O2.- into H2O2, acting as an 
efficient scavenger of free radicals [13]. Although the protective effects of tempol 
against free radical-induced damage have mainly been attributed to the 
dismutation of O2.-, tempol is a multifunctional antioxidant since it reacts with a 
diversity of biological oxidants and reductants [14,15]. 
Munzel et al. have recently reported that those patients with evidence of 
vascular oxidative stress have a worse prognosis in the management of 
hypertension [16]. It stands to reason that antioxidants should be beneficial in 
preventing and/or delaying hypertension. Moreover, it has been demonstrated 
that chronic treatment with acetylsalicylic acid lowers basal levels of O2.- in 
normotensive rats. However, pitfalls of conventional antioxidant therapy in 
conjunction with the lack of proven benefit of antioxidants have led to suggest 
that the use of supplemental antioxidant could even be hazardous to patients 
resulting in an “antioxidant paradox” [17]. Nevertheless, it is important to note 
that basic and clinical evidences showing cardiovascular benefits of antioxidant 
supplement are lacking.  
Taking into account that the mechanism of action of nebivolol includes 
eNOS stimulation, we hypothesized that administration of tempol, a O2.- 
scavenger, could decrease basal levels of ROS produced by the constitutive 
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action of vascular NAD(P)H oxidase improving the hypotensive response of 
nebivolol via NO increased bioavailability. 
2. Methods 
2.1 Chemicals 
Glybenclamide, N-acetyl-cysteine and thiobarbituric acid were from 
Sigma (St.Louis,MO,USA). Metoprolol and atenolol were purchased from 
Droguerias Saporiti (Buenos Aires, Argentina). Nebivolol was a gift from Raffo 
Laboratory (Buenos Aires, Argentina). All other reagents were of analytical 
grade or better. 
2.2 Animals 
2.2.1 Animals and chronic treatment of tempol 
Male Sprague Dawley rats (3 months old, 220–250 g) were purchased 
from the School of Pharmacy and Biochemistry, University of Buenos Aires, 
Argentina. Animal experiments were performed in accordance with the 
Principles of Laboratory 
Animal Care (NIH publication 2002 and 2011). The animal experiments 
were approved by the local Scientific and Technology Ethics Committee at the 
University of Buenos Aires. All efforts were made to minimize animal suffering 
and to reduce the number of animals used. Rats were randomly divided into two 
groups. Control rats (C, n = 46) were given tap water to drink and tempol group 
(T, n = 60) was given tempol solution at a concentration of 172 mg/L to drink for 
1 week [14]. For the N-acetyl-cysteine group (n=5), the drug was given in the 
drinking water at 4 g/kg/day during one week. 
2.3 Preparation of nebivolol formulation 
Nebivolol is practically insoluble in water and therefore a special formula 
was prepared to allow intravenous administration of the drug at a dose of 3 
mg/kg. The formula of nebivolol solution consisted of 2 mg/ml nebivolol, 
0.5%(w/v) polyvinylpyrrolidone, 40% (v/v) propylene glycol, 10% (v/v) glycerine 
and purified water. 
2.4 In vivo experiments 
2.4.1 In-vivo experimental design 
Rats were anaesthetized with ether and the left carotid artery and left 
femoral vein were cannulated with polyethylene cannulae containing 
heparinized saline solution (25 U/ml) for blood pressure recording and drug 
administration, respectively. Cannulae were tunnelled under the skin and 
externalized at the back of the neck. Experiments were performed in freely 
moving animals 24 h after cannulae placement. On the day of the experiment, 
arterial cannulae were connected to a Spectramed P23XL pressure transducer 
(Spectramed, Oxnard, CA, USA) coupled to a Grass 79D polygraph (Grass 
Instruments, Quincy, MA, USA). The polygraph was connected to a digital 
converter adaptor unit (Polyview, PVA 1; Grass-AstroMed,WestWarwick, RI, 
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USA), and recordings were stored and analysed with a software program 
(Polyview 2.3;Astro-Med,WestWarwick, RI, USA). Basal mean arterial pressure 
(MAP) and heart rate (HR) were estimated during an interval of 45 minutes. 
MAP was calculated as the sum of the diastolic pressure and one-third of the 
pulse pressure. HR was estimated tachographically by counting the pulsatile 
waves of arterial pressure recording. Nebivolol, at a dose of 3 mg/kg was 
injected intravenously during 30 s to the control group (CN, n=7) or tempol 
treated group (TN, n=7). To test different β-blockers responses, metoprolol (3 
mg/kg, i.v., n=5) or atenolol (3 mg/kg, i.v., n=5) was given to the T group. To 
determine the role of NOS or KATP channels in the cardiovascular effects of 
nebivolol, the blood pressure response was evaluated in rats pretreated, 45 min 
before nebivolol administration, with L -NAME (75 mg/kg, i.v.) or glybenclamide 
(20mg/kg) in the TN group (n = 5, in each group). The indicated dose of L-
NAME was chosen because it is specific only for the eNOS isoform [18]. 
2.4.2 Spectral analysis 
Blood pressure variability was continuously estimated by determination 
of standard deviation (SD) and spectral analysis of 3 min periods of blood 
pressure recordings were obtained from baseline and during regular times after 
nebivolol administration when the quality of the arterial blood pressure signal 
was visually considered to be satisfactory. According to previous work by other 
authors [19,20], spectral analysis of the data was performed using the Fast 
Fourier Transform algorithm with a Hamming window (Polyview 2.3;Astro-Med). 
Spectral densities in the very low frequency range (VLF) (0.1–0.2 Hz) and in the 
low frequency range (LF) (0.2 to 0.7 Hz) were estimated [20]. 
2.5 Ex vivo experiments 
2.5.1 Lipid peroxidation in control and tempol groups 
The thoracic aortic rings from the two groups were excised (C and T), 
washed with ice-cold saline solution (0.9% wt/vol NaCl), and weighed. 
Homogenate lipid peroxidation was determined by measuring the rate of 
production of thiobarbituric acid reactive substances (TBARS) (expressed as 
malondialdehyde equivalents) in the C and T, 7 animals in each group as we 
previously described [21]. 
2.5.2 Expression of α, β sGC isoforms, phospho-eNOS, eNOS and P-
VASP by Western Blot 
The animals were sacrificed by cervical dislocation, and thoracic aortic 
segments from the four experimental groups (C, T, CN and TN) were excised, 
washed with ice-cold saline solution (9 g/l NaCl) and weighed. Aortic 
homogenates from C, T for alpha (α), beta (β) guanylate cyclase and C,T, CN 
and TN groups for phospho-eNOS (Ser1177) and P-VASP (Ser 239) were 
prepared in a Potter-Elvehjem homogenizer using radioimmuno precipitation 
assay and Roche Complete Protease inhibitor tablets. The homogenates were 
then separated by centrifugation at 6,000 g for 20 min, and the supernatant was 
mixed with Laemmli 6 X loading buffer and incubated at 92 ° C for 5 min. Total 
tissue protein was separated by electrophoresis in 4-20 % Tris-glycine SDS 
polyacrylamide gels (Mini Protean III System; BioRad Laboratories, Hercules, 
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Calif., USA), transferred onto nirocellulose membranes and blocked in 50 g/l dry 
milk or bovine serum albumin in T-TBS (0.02 mol/l Tris, 0.15 mol/l NaCl, pH 7.5, 
containing 1 g/l Tween 20) at room temperature for 1 h. The membranes were 
washed 3 times with T-TBS and incubated with the primary antibodies against 
alpha (α), beta (β) sGC, phospo-eNOS (Ser 1177), total eNOS and P-VASP 
(Ser 239) overnight at 4° C. The polyclonal antibodies against α, β guanylate 
cyclase, were purchased from Sigma (St. Louis, MO., USA), and the monoclonal 
antibodies against phospo-eNOS, total eNOS and P-VASP were purchased 
from Cell Signaling Technology, Inc. (Danvers, Mass., USA). After washing 3 
times with T-TBS, the blots were incubated with horseradish peroxidase-
conjugated anti-rabbit secondary antibody at room temperature for 2 h. 
Thereafter, the membranes were washed 3 times with T-TBS, developed using 
enhanced chemiluminescent reagents (Amersham Life Science, Arlington 
Heights, IL, USA), and subjected to autoluminography for 1–5 min. Band 
intensities were quantified using the ImageJ software (NIH). In all instances, the 
membranes were stained with Ponceau S stain to verify the uniformity of protein 
loading and transfer efficiency across the test samples. Immunoblot with anti- β-
actin (Sigma-Aldrich) was used as an internal control of protein loading when 
correspond. The intensity values were first normalized to β-actin or total protein 
and then expressed as relative protein expression, with the control lane being 1 
unit. 
2.5.3 Aortic cGMP levels 
The thoracic aortic rings from the four groups C,T, CN and TN were 
excised, washed with ice-cold saline solution (0.9% wt/vol NaCl), and weighed. 
Aortic cGMP concentrations were measured using a cGMP ELISA kit (GE 
Healthcare, Pittsburgh, USA) according to the protocol of the manufacturer 
(acetylation enzyme immunoassay procedure for intracellular cGMP 
measurement). 
2.5.4 NO levels in ex vivo aorta 
Aorta rings from C and T rats were removed and placed in Krebs-
Henseleit buffer while trimmed free of adipose and connective tissue, and then 
cut into 4- to 5-mm rings. Aortic rings were placed in test tubes containing 2 ml 
Krebs solution and with 5 μM DAF-2DA for 30 min to allow intracellular 
accumulation of DAF-2 and aerated with 95% O2-5% CO2. After that, the aortic 
rings were further treated with 10 nM nebivolol or vehicle control. Samples for 
the basal accumulation of NO were taken. Then, aortic rings were removed, 
dabbed dry with filter paper, and weighed. The fluorescence of the incubation 
solutions was measured (50 μl, in triplicate) in a 96-well microplate using a 
SpectraMax M5 Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, 
CA, USA) at an excitation wavelength of 495 nm and an emission wavelength of 
520 nm. DAF-2DA fluorescence is linearly related to the NO concentration. NO 
production was expressed as steady-state DAF-2DA fluorescence intensity 
minus its intensity before exposure to the released NO and values were 
normalized to tissue weight and expressed taking the control group as 1 unit 
[22,23]. 
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2.5.6 NO metabolites 
NO metabolites content (NOx) was determined by means of the Griess 
colorimetric reaction, after enzymatic reduction of nitrates to nitrites in aorta 
homogenates. The absorbance of the samples was determined at 540 nm, and 
sodium nitrate was used as a standard. Results were expressed taking the 
control lane as 1 unit [24]. 
2.6 Statistical analysis 
Normal distribution of the data and the variables of the study were 
verified using the Kolmogorov–Smirnov test. Data were expressed as means ± 
SEM. Statistical analysis of drug effects on MAP, HR, western blot analysis, NO 
measurements was performed by two-way ANOVA. Comparison of drug 
interventions on LF and LVF was performed by one-way analysis of variance 
(ANOVA) and the test of Bonferroni as post hoc test. Statistical tests were 
performed using GraphPad Prism version 5.02 for Windows (GraphPad 
Software, San Diego, California, CA). Statistical significance was defined as p< 
0.05. 
3. Results 
3.1 Temporal course of mean arterial pressure changes after intravenous 
administration of nebivolol 
In the control group, nebivolol administration at a dose of 3 mg/kg did not 
modify the MAP at any time (Fig. 1A). Interestingly, in the group pretreated with 
the antioxidant tempol, nevibolol produced a marked decrease in MAP (Fig 1A). 
Conversely, vehicle did not modify blood pressure in either experimental C and 
T groups (data not shown). 
To rule out whether the increase in the hypotensive effect of nebivolol in 
the tempol treated groups was due to its β-blocker adrenergic action, we used 
metoprolol or atenolol, two β-blocker agents lacking an effect on NO 
bioavailability [12]. We have previously demonstrated that nebivolol at a dose of 
3 mg/kg is equivalent to a dose of 3 mg/kg of atenolol or metoprolol in regard to 
the MAP response [25,26]. Atenolol or metoprolol administration did not modify 
MAP neither in C nor T treated group (Fig. 1B). Also, to exclude whether the 
hypotensive effect was exclusive between tempol-third generation beta blockers 
association, we used N-acetyl cysteine (an antioxidant that mimics the action of 
glutathione) together with nebivolol. Surprisingly, in the N-acetyl cysteine group, 
nebivolol administration diminished MAP similar to the tempol preteated group 
(Fig. 1B). To address whether the hypotensive response in the TN group was 
related to an increase in NO level or KATP channel activation, we used L-NAME, 
a specific inhibitor of NOS, or glybenclamide, a KATP channel blocker. Acute 
preadministration of L-NAME partially blocked the hypotensive effect found in 
the TN group (Fig. 1A). Conversely, glybenclamide preadministration, did not 
modify the hypotensive response in the TN group (Fig. 1A). 
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3.3 Heart rate effects 
Figure 2 shows the maximum response of HR changes in C and T rats 
after intravenous administration of nebivolol, metoprolol or atenolol. Nebivolol, 
metoprolol and atenolol administration induced a bradycardic response in both 
control and tempol groups compared to C group. However, no significant 
statistically difference was found between groups. Vehicle application did not 
modify HR in C and T experimental groups without nebivolol, metoprolol or 
atenolol administration (data not shown). 
3.4 Effect of nebivolol on blood pressure variability 
Nebivolol administration reduced VLF and LF in the TN group at 15 and 
30 minutes post-administration (Table 1) with regard to control animals. 
However, reduction of VLF induced by nebivolol administration was not 
significant in the TN group compared with CN animals due to large variance of 
the results. Importantly, L-NAME pretreatment prevented effects on blood 
pressure variability demonstrating indirect evidence of the involvement of NO 
pathway in nebivolol-tempol synergic interaction (Table 1). 
3.5 Oxidative stress parameters 
3.5.1 Lipid peroxidation in aorta 
In order to demonstrate that tempol exerts antioxidant effects in the 
normotensive C group, we performed TBARS determination as a general index 
of oxidative stress. As shown in Fig. 3, pretreatment with tempol produced a 
decrease in TBARS formation in 30% in comparison with control without 
antioxidant treatment indicating that tempol treatment produced an antioxidant 
response. 
3.6 Nitric oxide pathway 
3.6.1 Effects of Nebivolol on NO/cGMP levels 
Nebivolol administration increased eNOS activation in the control and 
tempol pretreated groups. As shows in Fig. 4A, CN and TN rats showed a 1.58 
and 1.68 fold higher phosphorylation of ser 1177 than C and T groups, 
respectively (Fig. 4A). However, no statistical difference was found between CN 
and TN groups. Then, we measured NO level to find whether there was any 
difference between the CN and TN groups. The NO levels, measured by 
fluorescent probe DAF-2T in aortic rings, were increased in the CN group. 
Interestingly in the TN group, NO fluorescence was higher than CN group (Fig 
4B). Furthermore, the nitrite production measured ex vivo by Griess reaction 
was increased 3.2 folds in the TN group and 2.1 folds in the CN group with 
respect to C group without treatment, demonstrating an increase in NO 
bioavailability in the TN group compared to CN animals (Fig. 4C). 
3.6.2 Effects of Nebivolol on NO/cGMP signalling in tempol treated rats 
It is well know that NO exerts its biological action through the sGC 
enzyme. Data here reported demonstrates an increase in α and β sGC subunits 
in 2.1 fold expression in T group with respect to C animals (Fig. 5 A, B). In 
addition, cGMP, the effector of the NO pathway, was enhanced in TN when 
compared with CN group (Fig. 5C). It is well known that the primary downstream 
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target of vascular smooth muscle cGMP is PKG, which itself activates the VASP 
protein by phosphorylation. TN group showed a greater increase on P-VASP 
(ser 239) phosphorylation compared with CN (4.01 vs 2.20 fold, respectively), 
(Fig. 5D). This fact may be a consequence of increase in NO bioavailability 
together with the higher expressions of α and β guanylate cyclase found in the T 
and TN groups. 
4. Discussion 
The present study demonstrates that the combination of an antioxidant, 
such as tempol, and nebivolol, a NO-dependent vasodilatory beta blocker, 
produces a marked potentiation of nebivolol hypotensive response by 
enhancing NO bioavailability and the NO pathway, as a consequence of the 
antioxidant activity exerted by tempol. Our findings open a possible new 
strategy therapeutic. 
We have demonstrated that nebivolol at doses of 0.3 and 3 mg/kg did not 
modify mean arterial pressure in normotensive conscious rats [27]. However, 
dual combination between tempol and nebivolol i.v administration at a dose of 3 
mg/kg produces a drop in MAP without affecting HR substantially between the 
C, T, CN and TN groups. To address the mechanism involved in the 
hypotensive response, we test the possibility whether pretreatment with a NOS 
inhibitor, L -NAME, or with a KATP blocker, glybenclamide, could abolish this 
response found in the TN group. L-NAME but not glybenclamide partially 
blocked the drop in MAP in the TN group demonstrating that the NO pathway 
was involved in the hypotensive response to nebivolol in tempol pretreated rats. 
This last finding could be attributed to the endothelial isoform of NOS, 
considering that L -NAME, at the selected dose, is specific for eNOS [18]. 
Identification of the frequency components of blood pressure variability 
by power spectral analysis can potentially provide an approximation about 
mechanisms involved in blood pressure regulation [28-30]. In this context, it is 
well known that the endothelial-derived NO in rats modulates LF and VLF 
domains of blood pressure variability [28-30]. In fact, spectral analysis of the 
blood pressure recording suggests that the greater hypotensive response to 
nebivolol in tempol rats could be attributed to the NO pathway since nebivolol 
administration induced a reduction of VLF and LF only in the TN group. 
On the other hand, metoprolol and atenolol, two β blockers without 
eNOS stimulating activity did not produce any hypotensive response in animals 
pretreated with tempol. All together, these findings suggest that the 
improvement of the NO pathway could be attributed to an increase in NO 
bioavailability and/or a decrease in ONOO- production. Those are beneficial 
effects since arterial hypertension is associated with impaired endothelium-
dependent vasodilatation both in the macro and microvasculature [31,32]. 
Endothelium-dependent vasodilatation is mediated principally by NO and O2.- 
increased levels are associated with reduced NO bioavailability and increased 
ONOO-. O2.- is constitutively produced by the vascular NAD(P)H oxidase not 
only in pathological situation as hypertension but also in normotensive animals. 
For that reason, O2.- seems to play a key role for the reduced endothelium-
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dependent vasodilatation in arteries from normotensive and hypertensive 
animals leading and/or aggravating hypertension, as a consequence of eNOS 
uncoupling or ONOO- production [33,34]. Also, it has been shown by Oelze et 
al., that long-term nebivolol administration exerts antioxidant “perse” actions in 
an angiotensin-II dependent model of hypertension [16]. Nevertheless, in our 
study, the acute term of nebivolol administration is unlikely to produce neither 
antioxidant properties “perse” nor hypotension in the C group (Fig. 1). 
In order to elucidate the mechanism of the tempol-nebivolol hypotensive 
effect, we studied in more detail the NO/sGC/cGMP pathway [35,36]. The two 
most important sites of eNOS activation are the activation at Ser 1177 and the 
inhibitory site Thr 495 [35, 36]. In fact, in our experimental work, nebivolol 
induces phosphorylation at Serine 1177 in the control and tempol treated 
groups. This phosphorylation at Serine 1177 was similar in CN and TN groups; 
indicating that nebivolol-tempol amplified response is downstream eNOS 
activation. To address whether the hypotensive response was due to an 
increase in NO bioavailability, as a consequence of O2.- basal levels reduction 
by tempol action, we evaluate NO directly by DAF and indirectly by Griess 
reaction. As expected, NO and nitrite levels are increased in the TN group with 
respect to the CN group. In the vessel wall, NO diffuses from the endothelium 
across cell membranes into underlying vascular smooth muscle. It is known that 
the well-recognized function of NO is the activation of heme containing sGC 
[37], which is a heterodimeric protein consisting of 73 kDa α1 and 70 kDa β1 
subunits, both of which are required for catalytic activity [38,39]. sGC catalyses 
the conversion of guanosine-5'-triphosphate to the second messenger cGMP. In 
our study, we measured the cGMP levels in the four experimental groups. 
Consistently, TN group showed higher level in cGMP than CN group. In 
addition, chronic administration of tempol produced an increase in α1and β1 
sGC subunits expression and this last fact may enhance the hypotensive effect 
of nebivolol found in the TN group. cGMP modulates numerous targets, 
including protein kinases such as PKG, ion channels, among others [38]. 
However, the primary downstream target of vascular smooth muscle cGMP is 
PKG, which itself activates the myosin light-chain phosphatase [37]. Taking 
together, the NO-cGMP pathway is a key regulator of vascular tone and that 
PGK mediates many of these NO/cGMP effects [39- 41]. 
It is well know that analysis of the phosphorylation of VASP at serine 239 
is a useful biomarker of PGK activity [41, 42] and therefore NO pathway activity. 
Importantly, we found an increase in P-VASP at serine 239 levels higher in the 
TN group compared with CN animals that correlates with cGMP and NO levels. 
These results suggest that the over-response in the NO/cGMP pathway as a 
cause of the hypotensive effect in the TN group.  Nonetheless, we can not 
discard a role of ONOO- into this effect. Since O2.- reacts with NO producing 
ONOO-, another diverging mechanism could be that tempol-nebivolol 
association may reduce ONOO- levels preventing more eNOS declouped. 
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Conclusion 
Up to now, there are no data available on a successful combination 
between antioxidant and antihypertensive drugs. Moreover, monotherapy with 
vitamin C or vitamin E were found to lower oxidative stress, but large scale 
clinical studies have not supported an effect of vitamin C or vitamin E 
supplementation on cardiovascular disease or mortality [43,44]. 
Taking together our results, we demonstrated that antioxidant therapeutic 
with tempol produces an enhanced hypotensive effect in nebivolol 
administration enhancing the NO bioavailability and sGC improving the 
NO/cGMP/PKG pathway. Also, into this mechanism, we can not discard a 
possible reduction of ONOO- levels as a consequence of less O2.-. Since, 
ONOO- mediated oxidation of tetrahydrobiopterin, a critical cofactor for eNOS, 
which represents a pathogenic cause of uncoupling of NO synthase, tempol-
nebivolol combination could be preventing this phenomenon through decreasing 
nitrosative stress. 
To sum up, this association could lead to a new therapeutic strategy for 
treatment of hypertension or resistant hypertension to standard therapy. The 
mechanism proposed is that the reduction of O2.- constitutively produced by 
NADPH or ONOO- levels by tempol action, could enhance the NO bioavailability 
produced by third generation β-blocker releasing NO. Further studies are 
needed to establish whether the ability of this combination could attenuate 
hypertension in experimental models or in humans. 
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Figure Legends 
Fig. 1. Changes on MAP after nebivolol (3mg/kg), i.v. administration in control 
(CN), tempol rats (TN) and TN animals preteated with L-NAME (75 mg/kg) or 
glybenclamide (20 mg/kg). Changes in MAP were described as the changes in 
intravascular administration of nebivolol. Values are the means ± SEM of 
multiple experiments (n = 7, in each group). * p<0.05 versus before 
administration. # p<0.05 versus TN group. B) Changes on MAP after metoprolol 
or atenolol (3mg/kg), i.v. administration in control (C) and tempol rats (T) and 
changes on MAP after nebivolol (3mg/kg), i.v. administration in N-Acetyl-
Cysteine preteated group. Changes in MAP were described as the changes in 
intravascular administration of nebivolol. Values are the means ± SEM of 
multiple experiments (n = 5, in each group). * p<0.05 versus before 
administration. 
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Fig. 2. Maximum changes on heart rate (HR) after nebivolol, metoprolol or 
atenolol (3 mg/kg), i.v. administration in control (CN), tempol rats (TN) and TN 
animals preteated with L-NAME (75 mg/kg). Changes in HR were described as 
the changes after intravascular administration of nebivolol, metoprolol or 
atenolol. Values are the means ± SEM of multiple experiments (n = 7, in each 
group). * p<0.05 versus baseline value. 
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Fig. 3. Lipid peroxidation in C and CT rats. Bars represent mean ± S.E.M of 7 
animals in each group. * p < 0.0001 tempol versus control group, n=7 each 
group. 
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Fig. 4. (a) eNOS phosphorilation in the thoracic aortic homogenates of C,T, CN 
and TN after 10 minutes of nebivolol (3 mg/kg, i.v.) in vivo administration. 
Relative expression level of phospho-eNOS. Phospho eNOS was normalized 
using total eNOS antibody, and results are expressed as relative to a control of 
1. * Significant differences ( p<0.01) between nebivolol administration groups vs 
control group. Results show mean values of four independent measurements. b) 
NO measurement by fluorescence analysis of DAF-2 T (triazolofluorescein). 
Aortic rings from C and T groups were pretreated with nebivolol (10 μM) ex vivo 
during 10 minutes before addition of DAF-2 (5 μM). Concentrations of the 
product DAF-2 T were analyzed by fluorescence. Reported data are DAF-2 T 
concentration normalized to dryed tissue weight in each sample and expressed 
taking control group as 1. * P<0.05. Line (P<0.05) represents differences 
between CN and TN groups, n=5 each group. c) Nitrite measurement by Griess 
reaction. Aortic rings homogenates from C, CN, T and TN groups after 10 
minutes of nebivolol (3mg/kg) i.v. in vivo administration. * significant differences 
( p<0.01) between nebivolol administration groups vs control group. Line 
(p<0.05) represents differences between CN and TN groups, n=7 each group. 
Values were normalized to protein content in each sample and results are 
expressed as relative to a control of 1. 
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Fig. 5. NO pathway protein expression. Alpha (A) and beta (B) sGC protein 
expression in the thoracic aortic homogenates from C and T groups. Protein 
expression was normalized using β -actin as control antibody, and results are 
expressed as relative to a control of 1. * Significant differences ( p<0.01) 
between T group vs control group. Results show mean values of four 
independent measurements. (c) cGMP measurement in aortic rings 
homogenates from C, CN, T and TN groups after 10 minutes of nebivolol 
(3mg/kg) i.v. in vivo administration. * significant differences ( P<0.05) between 
nebivolol administration groups vs control group. Line (P<0.05) represents 
differences between CN and TN groups. Results show mean values of four 
independent measurements. (d) P-VASP (ser 239) in the thoracic aortic 
homogenates of C,T, CN and TN after 10 minutes of nebivolol (3 mg/kg, i.v.) in 
vivo administration. Relative expression level phospo-VASP. Phospho-VASP 
was normalized using beta actin antibody, and results are expressed as relative 
to a control of 1. * significant differences ( P<0.01) between nebivolol 
administration groups vs control group. Line (P<0.05) represents differences 
between CN and TN groups. Results show mean values of four independent 
measurements. 
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Table Legends 
Table 1 
Change in beat-to-beat blood pressure variability in the low frecuency (LF) and 
very low frequency (VLF) domain (expressed as % of baseline values) after 15 
and 30 min of i.v. administration of nebivolol in control rats (CN), tempol rats 
(TN) and tempol rats pretreated with L-NAME (TN-LNAME). Bars represent 
mean ± S.E.M of 7 animals in each group. * P<0.05 vs. CN. 
Parameter CN TN TN-LNAME 
LF variability (mmHg2) 
(15 min) 
 
91.58±12.85 
 
48.10±4.80* 
 
100.19±12.07 
(30 min) 82.74±5.35 53.21±2.12* 99.90±7.14 
VLF variability 
(mmHg2) 
(15 min) 
 
95.78±11.42 
 
65.62±13.40 
 
89.51±10.50 
(30 min) 93.78±2.44 74.48±7.41 107.42±12.53 
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